South San Francisco, Calif. — October 29, 2025 — Leads & Copy — CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) announced that Nasdaq trading of its shares of common stock will be suspended at the open of trading on October 31, following the determination of the Nasdaq Hearings Panel to deny the Company’s request to continue its listing.
CERo plans to appeal the Panel’s determination, seek trading of its shares on the OTC Markets, and continue clinical operations. The Panel decided the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires stockholders’ equity of at least $2.5 million.
The Panel’s decision was based upon a retroactive determination of non-compliance as of April 22, 2025, without regard to the Company’s plan for regaining compliance. CERo has executed portions of its plan, including the receipt of approximately $2.25 million of cash proceeds from the sale of Series E Convertible Preferred Stock.
The Company has submitted a request for review of the Panel’s decision by the Nasdaq Listing and Hearing Review Council and commenced the process of seeking to trade its shares on the OTC Markets.
CERo currently plans to continue its clinical trials. Evidence gathered for CER-1236 in the first three AML cancer patients dosed at the initial low dose showed rapid cell expansion of CER-1236 in these patients, along with observation of no toxicity.
Chris Ehrlich, Chief Executive Officer, can be reached at chris@cero.bio. Investors can contact CORE IR at investors@cero.bio.
Source: CERo Therapeutics Holdings, Inc.
Source: CERo Therapeutics Holdings, Inc.
